Enfortumab Vedotin for Previously-Treated Advanced Urothelial Carcinoma

HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemoПодробнее

Enfortumab Vedotin Appears Well-Tolerated and Active in Advanced Bladder CancersПодробнее

Enfortumab vedotin plus pembrolizumab for advanced urothelial carcinomaПодробнее

Enfortumab vedotin for the treatment of advanced urothelial cancerПодробнее

Bladder cancer highlights at ASCO 2022Подробнее

Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial CarcinomaПодробнее

Enfortumab vedotin as treatment for urothelial carcinomasПодробнее

24-month findings from EV-301: enfortumab vedotin vs chemotherapy in previously treated advanced UCПодробнее

Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial CarcinomaПодробнее

Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?Подробнее

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer | Robert DreicerПодробнее

Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Cancer | NEJMПодробнее

The role of enfortumab vedotin in earlier lines and stages of urothelial cancer | Arjun BalarПодробнее

EV-301: Enfortumab vedotin boosts advanced urothelial cancer survival | Thomas PowlesПодробнее

EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancerПодробнее

EV-103 Cohort H: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible MIBCПодробнее

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancerПодробнее

EV-201, EV-301 and UNITE: enfortumab vedotin in advanced urothelial cancerПодробнее

UNITE: enfortumab vedotin in advanced urothelial cancerПодробнее

EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC | Jonathan RosenbergПодробнее